[The risks of long-term proton pump inhibitors use]

Area of Science:

• Gastroenterology
• Pharmacology
• Endocrinology

Context:

• Proton pump inhibitors (PPIs) are widely prescribed for acid-related gastrointestinal disorders.
• Long-term PPI use necessitates understanding potential associated health risks.
• This study investigates the effects of prolonged PPI intake on specific biochemical markers and bone density.

Purpose:

• To explore the potential risks associated with long-term proton pump inhibitor (PPI) use.
• To evaluate the impact of extended PPI therapy on serum levels of gastrin, vitamin B12, and various minerals.
• To assess changes in bone density, particularly in the hip and lumbar spine, among long-term PPI users.

Summary:

• A study compared 79 long-term PPI users with 47 controls, measuring bone density and serum levels of gastrin, vitamin B12, magnesium, calcium, and other minerals.
• Results indicated a slight decrease in hip bone density and elevated serum gastrin in the PPI group compared to controls.
• No significant differences were observed in serum vitamin B12, calcium, copper, iron, or zinc levels between the groups.

Impact:

• Long-term PPI use, particularly at standard dosages, may be associated with a modest decline in hip bone density.
• Elevated serum gastrin levels were observed in patients on long-term PPI therapy.
• The findings suggest that while PPIs may affect bone density and gastrin, their impact on key vitamins and minerals is minimal, warranting further investigation into bone health management for long-term users.